U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT06919939) titled 'Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma' on April 02.
Brief Summary: The purpose of this study is to determine whether combining Loncastuximab Tesirine with Epcoritamab is tolerable and effective for reducing and/or eliminating lymphoma cells in the body.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Large B-cell Lymphoma
Relapse
Intervention:
DRUG: Epcoritamab
Epcoritamab will be administered via subcutaneous injection at the following dose levels and schedule over a total of twelve cycles:
* Cycle 1 Day 1: Step-up dose of 0.16 mg
* Cycle 1 Day ...